"Evolocumab Reduces LDL, non-HDL in High-Risk Patients With Type 2 Diabetes" - Katie Kalvaitis
Treatment with the PCSK9 inhibitor evolocumab on top of maximally tolerated statin therapy resulted in significant reductions in LDL cholesterol and non-HDL cholesterol among patients with type 2 diabetes and hypercholesterolemia or mixed dyslipidemia enrolled in the BANTING study. The findings were reported at the American Diabetes Association Scientific Sessions. “These data are important, as they demonstrate that additional treatment options, such as Repatha, can help further reduce LDL and non-HDL in patients who are unable to reach targets with high-intensity statin therapy alone,” said Robert Rosenson, director of Cardiometabolic disorders at the Icahn School of Medicine at Mount Sinai.
- Robert Rosenson, MD, Professor, Medicine, Cardiology, Director, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai